Stronger Together

The pharmacological landscape for treating endometriosis and uterine fibroids has been revolutionized by the widespread adoption of oral, non-peptide gonadotropin-releasing hormone (GnRH) antagonists.

Unlike the older generation of injectable agonists that caused an initial "flare" of symptoms, 2026 therapeutics like Elagolix, Relugolix, and Linzagolix provide rapid, dose-dependent suppression of ovarian estrogen production. This precision allows clinicians to "titrate" the biological effect based on the severity of the patient's symptoms, effectively starving estrogen-dependent lesions while minimizing bone density loss—a significant side effect of earlier treatments. Furthermore, the integration of "add-back therapy," which combines these antagonists with low-dose estradiol and norethindrone, has extended the safe duration of treatment to 24 months and beyond, providing a viable non-surgical alternative for women who wish to preserve their fertility or avoid hysterectomy.